Avalanche Biotechnologies Reports Fourth Quarter and Fiscal 2015 Financial Results
Avalanche Biotechnologies to Present at Upcoming Investor Conferences
Avalanche Biotechnologies and Annapurna Therapeutics Announce Proposed Merger
Avalanche Biotechnologies, Inc. Names Paul B. Cleveland as CEO
Avalanche Biotechnologies, Inc. Reports Third Quarter 2015 Financial Results
Avalanche Biotechnologies, Inc. Reports Second Quarter 2015 Financial Results and Provides Update on AVA-101 Program
Avalanche Biotechnologies Awarded as Technology Pioneer by World Economic Forum
Avalanche Biotechnologies Announces Leadership Transition
Avalanche Biotechnologies, Inc. Announces Positive Top-Line Phase 2a Results for AVA-101 in Wet Age-Related Macular Degeneration
Avalanche Biotechnologies Presents Three Posters at American Society of Gene & Cell Therapy (ASGCT) Annual Meeting